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B cells are critical for promoting autoimmunity and the success of B cell depletion therapy
in rheumatoid arthritis (RA) confirms their importance in driving chronic inflammation.
Whilst disease specific autoantibodies are useful diagnostically, our understanding of the
pathogenic B cell repertoire remains unclear. Defining it would lead to novel insights and
curative treatments. To address this, we have undertaken the largest study to date of over
150 RA patients, utilizing next generation sequencing (NGS) to analyze up to 200,000
BCR sequences per patient. The full-length antigen-binding variable region of the heavy
chain (IgGHV) of the IgG B cell receptor (BCR) were sequenced. Surprisingly, RA patients
do not express particular clonal expansions of B cells at diagnosis. Rather they express
a polyclonal IgG repertoire with a significant increase in BCRs that have barely mutated
away from the germline sequence. This pattern remains even after commencing disease
modifying therapy. These hypomutated BCRs are expressed by TNF-alpha secreting
IgG+veCD27−ve B cells, that are expanded in RA peripheral blood and enriched in the
rheumatoid synovium. A similar B cell repertoire is expressed by patients with Sjögren’s
syndrome. A rate limiting step in the initiation of autoimmunity is the activation of B
cells and this data reveals that a sizeable component of the human autoimmune B cell
repertoire consists of polyclonal, hypomutated IgG+ve B cells, that may play a critical role
in driving chronic inflammation.
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INTRODUCTION
Rheumatoid arthritis (RA) is the commonest autoimmune inflammatory arthritis, affecting up
to 1% of the world’s population (1, 2). It is characterized by chronic systemic inflammation that
targets the synovial joints, leading to progressive joint damage and disability. Whilst pathogenesis
is incompletely understood, the pivotal role of B cells is supported by the efficacy of B cell
depletion therapy (BCDT) in the majority of treated patients (2–4). Auto-antibodies binding to
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post-translationally modified proteins (e.g., ACPA) or the
constant region of other immunoglobulins [rheumatoid factors
(RF)] (5), augment the generation of immune complexes.
However, there is a poor correlation between a good clinical
response to BCDT and a reduction ACPA titer (6, 7), suggesting
that other B cell specificities may be more important in
driving chronic inflammation. Sjögren’s syndrome is a systemic,
autoimmune, chronic inflammatory disease, characterized by
auto-antibodies and lymphocytic infiltration of exocrine glands.
It affects about 0.1% of the population but is three times
commoner in patients with RA. Currently there are no licensed
treatments that affect the prognosis of Sjögren’s syndrome and
RA remains incurable.
The advent of accessible, high throughput sequencing
technologies has enabled formal evaluation of differences
between the B cell repertoire of healthy and diseased individuals.
To date, studies characterizing the B cell repertoire of RA
patients have been limited in number, sample size or sequencing
depth (8). An appreciation of the expressed BCR repertoires in
RA patients would provide a more complete understanding of
disease pathogenesis. We hypothesized that RA patients would
have expansions of circulating pathogenic B cells at diagnosis,
that could also be detected as a conserved BCR signature in
established disease. Utilizing next generation sequencing (NGS)
of peripheral blood and synovial B cells, we sequenced the
repertoire of expressed BCRs, focusing on the main antigen
binding IgG variable heavy (IgGHV) region. We assessed 127
newly diagnosed RA patients, 16 patients with established RA and
8 paired blood and synovial samples. In addition, we phenotyped
peripheral blood B cells from an additional 64 RA patients
and 30 healthy controls. RA patients expressed significantly
more IgG+ve BCR sequences with fewer than five mutations,
which we refer to hereafter as hypomutated (or IgGhypoM). A
similar response was seen in patients with Sjögren’s syndrome.
The hypomutated IgGHV BCRs were polyclonal and originated
from IgG+veCD27−ve cells that secreted significantly more TNF-
alpha when stimulated, and which were significantly increased
in the circulation. We also detected minimal sharing of identical
IgGHV BCRs either between patients or between the synovium
and peripheral blood of the same patient. RA patients also
expressed significantly more IgG+veCD27−ve B cells that lacked
expression of CD24, CD38, and CD21, which are akin to double
negative 2 (DN2) (9) B cells known to be associated with more
severe, active systemic lupus erythematosus (SLE) (10, 11). The
prevalence of IgGhypoM expressing B cells leads us to hypothesize
that they may play a key role in driving chronic inflammation in
systemic autoimmunity.
MATERIALS AND METHODS
Ethical Review and Donor Selection
Criteria
The use of human samples for cohorts 1, 3, and 4 was approved by
the South East Scotland Bioresource NHS Ethical Review Board
(Ref. 15/ES/0094). Ethical permission to collect samples donated
to the SERA inception (cohort 2) was approved by the West of
Scotland Local Research Ethics Committee (Ref. 10/S0703/4) as
previously described (12). Informed consent was obtained from
all study participants prior to sample collection. Patient cohorts
are described in Supplementary Tables 1–4.
Flow Cytometry & FACS Sorting
PBMC were stained in PBS with 1% FCS for 20min at
4◦C. A BD Aria II was used for flow sorting and a BD
LSRII was used to collect data. All analysis was performed
using FlowJo software. Debris and dead cells were excluded
using FSC-SSC. Doublets were excluded using both FSC and
SSC singlet gating. The full gating strategy is shown in
Supplementary Figures 8, 9. A list of antibody reagents is shown
in Supplementary Table 6. Intracellular staining was performed,
following stimulation (for 4.5 h) with PMA [Sigma (20 ng/ml)] &
Ionomycin [Sigma (1µg/ml)]. After 1 h of stimulation Brefeldin
A [Sigma (1µg/ml)] was added for the remaining 3.5 h. Surface
staining was performed before fixation and permeabilization
using a Cytofix/Cytoperm kit (BD Biosciences).
Cell Purification
Peripheral blood mononuclear cells (PBMC) were prepared
from citrated blood samples using Ficoll R© Paque Plus density
centrifugation following manufacturer’s instructions (GE
Healthcare). Synovial tissue was dissected followed by digestion
for 2 h at 37◦C in 1mg ml−1 Collagenase 1 (Sigma-Aldrich).
Debris was removed and cells isolated by sequentially passing
through 100, 70 and 40µm cell strainers (Corning). PBMC and
synovial tissue were enriched for B-cells using either anti-CD19
magnetic beads or anti-CD20 (Miltenyi Biotech) as outlined in
Supplementary Table 5.
B Cell Repertoire Sequencing
B cell repertoire sequencing was performed as previously
described (13, 14), with the modifications described below.
Supplementary Table 5 specifies the individual amplification
strategies employed for samples from each cohort where
variations were present. mRNA was purified using mRNA direct
kit (Life Technologies), or total RNA was purified using either
a Direct-zol total RNA kit (Zymo Research) or a Paxgene blood
RNA kit (Qiagen). First strand cDNA synthesis was performed
using Superscript III first-strand synthesis supermix (Invitrogen)
or total cDNA synthesis kit (Applied Biosystems) according
to the manufacturer’s recommended protocols. For samples
where low cell counts were included (CD27 sorted B-cells and
synovial cells, as indicated in Supplementary Table 5), whole
transcriptome amplification was performed using Smartscribe
Reverse Transcriptase and Advantage2 PCR kits (Takara
BioEurope) following the Smart-Seq2 protocol (15). For all
samples, V-region amplicons were generated by PCR using
Phusion Flash polymerase (ThermoFisher Scientific) with
individual pools of forward primers within framework region
1 (FR1) designed to amplify all known V-region alleles, and
a reverse primer within the IgG or IgM constant regions
(Supplementary Figure 1). Samples were pooled and run on a
2% agarose gel and the dominant band was purified from an
excised gel band equivalent to 400–450 bp. 250 bp paired-end
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sequencing of the pool of PCR amplicons was performed on an
Illumina MiSeq sequencer using MiSeq Version 2 500 cycle kit
with a pool of read 1 sequencing primers, an indexing primer,
and read 2 constant region amplification primers. Read 1 and
read 2 sequencing primer sequences were identical to the pool
of amplification primers detailed in Supplementary Figure 1
but omitting the Illumina adaptor sequence. All sequence data
generated in this work has been deposited in the NCBI Short
Read Archive under project number PRJNA561156.
Immune Repertoire Analysis
Sequence read-pairs were trimmed to remove sequence below a
quality threshold of Q30 then combined into sequence contigs
using the FLASH utility version 1.2.11 (16), and sequences with
an overlap of fewer than 15 bp, or mismatch ratio of ≥0.25 were
excluded from further processing. Sequences were aligned to the
human germline V, D, and J segment alleles from the IMGT
database using the VDJfasta utility (17), with all sequences that
were successfully aligned to human IGMT V alleles being taken
forward for further analysis. Donors were excluded from the
study if the repertoire contained fewer than 25,000 total reads
after processing with VDJfasta as this was indicative of poor
sample preservation or preparation, and any such donors are not
shown in the patient information tables for this study. Mutation
counts and frequencies were generated from the VDJfasta utility,
as the number of nucleotide differences between the sequencing
read of each donor and the predicted germline Vh segment allele,
allowing the number of Vh segment mutations to be determined.
Frequency distributions for each donor were derived using the
ggplot2 (18) and plyr (19) packages of the R statistical package
(20). Skewness is a measure of the asymmetry of the distribution
about its mean, and was calculated as the adjusted Fisher-Pearson
standardized moment coefficient (21) using the skew method of
the Pandas Python library (22).
Clonal abundance analyses were performed by grouping all
reads with identical CDR3 amino acid sequences, where the
predicted germline Vh allele was identical. This clone was
assigned the mean number of hypermutations for all reads
contributing to the clone. Clonal clustering analyses, as shown in
Supplementary Figures 10, 11, were performed by first grouping
sequences by shared V gene, J gene, and junction length (23).
Clonal clusters then were generated by single-linkage clustering
of CDR3 sequences within a Hamming distance of 1. Repertoire
clonal overlap scores were used to assess repertoire similarity
(24), and were here calculated as the total number of reads from
shared clonal clusters between two samples, divided by the sum of
sequencing reads in both samples, with potential values ranging
from 0 to 1.
The Gini index was calculated for each sample based upon
the read counts for each unique complementarity determining
region 3 (CDR3) amino acid sequence in the repertoire,
according to the formula:
Gini index =
2
∑n
i i× yi
n
∑n
i yi
−
n+ 1
n
Analysis of the paired blood/synovial B cell data from study 4 was
performed by combining read pairs and prediction of germline
sequences pRESTO and Change-O, followed by processing using
the Alakazam package of the Immcantation adaptive immune
repertoire analysis framework (23, 25). No read count threshold
was applied to this data, but instead sequences were filtered using
the CollapseSeq tool to include only sequences with a duplication
count of 2 or greater.
B Cell Clone Lineage Tree Construction
Multi-compartmental clones (i.e., B cell clones which were found
in both peripheral and synovial B cells) were identified as B cell
clones containing at least 1 sequence present in each of the paired
peripheral blood and synovial samples from an individual donor.
Lineage trees of multi-compartmental clones were inferred using
PHYLIP v3.6 in Alakazam. The generated lineage trees were
exported from R as. GML files and graph layout was plotted
in Gephi v0.9.2. Nodes were colored according to sequence
mutation count and scaled according to the duplication count
of each sequence. Germline and inferred sequences were colored
white and set to the minimum node size. Graph layout was
calculated using the ForceAtlas 2 algorithm. The lineage trees of B
cell clones containing sequences that displayed evidence of index
misassignment were discarded.
Statistical Analysis and Data Visualization
Before performing inferential statistical tests, data were assessed
for conformity to the assumptions of the test used. The
assumption of normality of data was visually assessed using
the Q-Q plot method, generated using the StatsModels Python
package. Prism 6.0 (GraphPad Software Inc.) or the scipy.stats
Python package (26) was used to perform all Student’s T-tests,
Mann-Whitney, Wilcoxon and Kruskal-Wallis non-parametric
tests. Two-tailed p-values are given in all cases. All plots
were drawn with Prism (Graphpad Software Inc.) or with the
Matplotlib (27) or Seaborn Python packages, and data processing
used the Pandas package (22). Dunn’s post-hoc test was run using
the scikit-posthocs module (28). For analyses involving multiple
pairwise comparisons, p-value adjustment was performed using
the Holm-Šídákmethod (29). Use of the± followingmean values
indicates the 95% confidence interval.
RESULTS
RA Patients Express a Higher Frequency of
Hypomutated IgG B Cell Receptors Within
Peripheral Blood
200,000 highly purified CD19+ve B cells isolated from the
peripheral blood of each of 14 newly diagnosed treatment-
naïve seropositive early rheumatoid arthritis (ERA) patients
(cohort 1/Supplementary Table 1) and 16 healthy controls
were sequenced by NGS. The degree of mutation within
the IgG heavy chain (IgGHV) was calculated by assessing
the number of nucleotide mismatches between each sequence
read and the closest predicted germline V segment sequence.
Whereas, the number of mutations per IgG read approximated
to a symmetrical distribution in healthy individuals, the
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FIGURE 1 | (A) Distribution of the number of IgG-Vh mismatches per sequencing read for DMARD naïve early RA patients (ERA) (n = 14) and healthy control donors
(n = 16). Individual density plots are stacked to indicate the overall distribution across all samples in each group. Maximum cumulative density values for each group
are normalized to the mode to facilitate inter-group comparison. (B) Skewness of IgG mutation distributions from RA patients (n = 14) and healthy control groups (n =
16). Horizontal lines denote the arithmetic mean skewness for each group. P-value shown was calculated using Mann-Whitney U-test. (C) Distribution of the number
of V segment mismatches per sequencing read for ERA patients [cohort 2, n = 113]. Individual density plots are stacked to indicate the overall distribution across all
samples in each group. (D) Mean IgG-Vh mismatches for control donors (n = 16), ERA donors from cohorts 1 and 2 (n = 14 and n = 113, respectively), ESRA donors
from cohort 3 (n = 16), and Sjögren’s syndrome patients (n = 15). P-values are generated by Kruskal-Wallis test with Dunn’s post-test to compare the means for each
RA group with the control donor group. (E) Percentage of IgG reads with fewer than 5 mutations for control donors (n = 16), ERA donors from cohorts 1 and 2 (n =
14 and n = 113, respectively), ESRA donors from cohort 3 (n = 16), and Sjögren’s syndrome patients (n = 15). P-values are generated by Kruskal-Wallis test with
Dunn’s post-test to compare the median values for each RA group with the control donor group.
distribution of mutations in RA donors was skewed by
the presence of an increased frequency of poorly mutated
IgG sequences (Figures 1A,B; Supplementary Figure 2). This
observation was confirmed in a larger cohort of 113 newly
diagnosed, disease modifying anti-rheumatic drug (DMARD)
naïve, seropositive ERA patients, selected from the Scottish Early
Rheumatoid Arthritis (SERA) inception cohort (12) (cohort
2/Supplementary Table 2). A bimodal distribution of IgGHV
mutation counts was observed in the IgGHV sequences with
the first peak representing poorly mutated IgG sequences
(Figure 1C). To establish if this population persisted in patients
with established RA (ESRA), we sequenced the IgGHV sequences
from 16 ESRA donors (cohort 3/Supplementary Table 3A), and
to ascertain if IgGhypoM are a unique feature of RA, we also
sequenced the peripheral blood IgG-Vh repertoires of 15 patients
with primary Sjögren’s syndrome (Supplementary Table 3B).
Analysis of the mean IgG mutation count per read showed
that there were fewer IgGHV mutations in the ERA, ESRA
and Sjögren’s syndrome cohorts, compared to healthy control
donors (Figure 1D). A further 12 paired samples taken 6 months
following DMARD therapy (Supplementary Table 2) confirmed
that the mean number of IgGHV mutations was only slightly
increased [16.3± 2.4 compared with 12.8± 1.9 at diagnosis] (p<
0.006, Wilcoxon signed-rank test) (Supplementary Figure 2C).
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FIGURE 2 | (A) The mean number of IgG-Vh V segment mismatches per read for each individual in the ERA (cohort 2, n = 113) and healthy control groups (cohort 1,
n = 16). Data are split by germline IGHV family group. White circles denote group means, vertical white lines show the 95% confidence interval for the mean. (B)
Percentage of IgG reads that use the IGHV4-34 allele in ERA patients (cohort 2, n = 113) and control donors (cohort 1, n = 16). Horizontal bars denote group means,
and p-values calculated by Mann Whitney U-test. (C) Mean number of IgG-Vh mismatches per read for ERA donors (n = 113, cohort 2) and healthy control donors (n
= 16). For each donor, the mean number of mutations for all reads mapping to IGHV4-34, or to other IGHV alleles, were calculated and plotted independently, with
horizontal bars plotted to indicate the group mean. P-values calculated using Kruskal Wallis with Dunn’s post-hoc pairwise test, and with Holm-Šídák correction for
multiple comparisons of group means. (D) Proportion of IGHV4-34 reads of IgM and IgG isotype sequences where the carbohydrate binding AVY motif within
framework region 1 (IMGT numbering 24–26) is present. P-value calculated using Mann-Whitney test to compare the group means. (E) Proportion of IGHV4-34 IgM
and IgG isotype sequences where the NHS glycosylation motif within CDR2 (amino acid residues 57–59, IMGT numbering scheme) is present. P-value calculated
using Mann-Whitney test to compare the group means.
The skewed distribution of IgGHV mutation counts in ERA
donors were the result of an increased frequency of IgG sequences
with fewer than 5 mutations. Indeed, the mean percentage
of the IgG repertoire composed of fewer than 5 V-segment
mutations [hypomutated IgG sequences [IgGhypoM]] in the RA
cohorts was significantly higher than healthy controls (means
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FIGURE 3 | (A) Gini coefficients of IgG sequences for each RA donor from cohort 2 (n = 113). Gini coefficients are a measure of inequality of distribution, where a
value of 0 indicates perfect equality (all IgG clonotypes of equal proportion). The Gini coefficient was calculated independently for hypomutated (fewer than 5
mismatches) or hypermutated (5 or more mismatches) sequences to compare the degree of clonal expansion in each category. (B) Percentage of the IgG-Vh
repertoire composed of unique clonotypes from ERA patients and healthy controls (cohort 1, n = 14 + 16, respectively), with sequences split into hypermutated (5
mismatches or more) and hypomutated (fewer than 5 mismatches). For this analysis, clones were defined as having identical CDR3 sequences, sharing predicted V
segment identity and having the same number of V segment mutations. (C) Scatterplots showing the percentage of the repertoire against the hypermutation rate for
each clone for the three individual RA donors with the greatest frequencies of hypomutated B-cells (in cohort 1). Clone definition is the same as that used for (B).
with 95% confidence intervals were 12.6% ± 1.5 ERA patients
from cohorts 1 and 2, 8.4% ± 4.7 for ESRA, and 8.3% ± 2.2
for Sjögren’s patients, compared to the mean for healthy controls
of just 2.8% ± 0.9) (Figure 1E). The analysis of individual
cohorts is shown in Supplementary Figure 2D. In contrast,
there was no difference in the mean number of mutations
for IgM between ERA and healthy control populations,
possibly due to the inherently lower hypermutation frequency
of this isotype (Supplementary Figure 3). The frequency of
IgGhypoM and the disease activity 28 joint score (DAS28)
were not correlated, making it unlikely that the presence of
IgGhypoM was simply a result of more marked inflammation
(Supplementary Figure 2B). Nonetheless, the existence of this
hypomutated IgG population in both RA and Sjögren’s syndrome
patients suggests it is a generalized feature of failed B cell
tolerance, contributing to human autoimmunity.
Hypomutated Sequences Are Distributed
Throughout the IgG Repertoire in RA
A potential explanation for the increased frequency of IgGhypoM
in RA donors could be mono- or oligo-clonal expansion
of IgG B cell clonotypes with few mutations. However,
this was unlikely given that the IgGhypoM sequences were
not restricted to particular IGHV allele families (Figure 2A;
Supplementary Figure 4). The IGHV4-34 gene segment, that is
associated with self-reactivity and a failure of B cell tolerance
and autoimmunity (30–32) is censored at multiple check points
in healthy individuals (33). Yet, IGHV4-34 expression was
significantly higher in the IgG+ve B cells from 113 DMARD
naïve RA patients (2.41%, ± 0.43) compared to healthy controls
(0.65%, ± 0.16) (Figure 2B). Somatic mutations within the
IGHV4-34 gene reduce self-reactivity (34, 35) but the IGHV4-34
allele in RA IgG+ve BCRs expressed significantly fewer mutations
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FIGURE 4 | (A) Prevalence of hypomutated V segment sequences in CD27+ve and CD27−ve IgG+ve B-cells from RA and control donors. White spots indicate
individual data points for each donor (n = 4 donors per group). P-value calculated using Mann-Whitney test. (B) Whole blood was stained for flow cytometry to
(Continued)
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FIGURE 4 | determine cell number. IgD−ve IgM−veCD27−ve B cells were gated and cells/ml calculated. n = 35 HD donors, n = 39 RA (0m) donors, n = 38 RA (6m)
donors. P-value calculated using Mann-Whitney test. (C) Scatterplot of the frequencies of DN (IgD−ve IgM−veCD27−ve) B cells from paired baseline and 6-month data
from (B), to determine if the frequency of DN B cells was correlated in the same patient 6 months following DMARD therapy. n = 27 patients. R2 value calculated
using Pearson’s correlation. (D) Cell frequencies of CD20+veCD19+ve IgG+veCD27−ve B cells from PBMCs from control donors and RA patients assessed by flow
cytometry. Cells were gated for CD20+veCD19+ve IgG+ve B cells then the proportion of CD27−ve cells determined. n = 22 HD donors and 42 RA donors. P-value
calculated using unpaired T-test. (E) Cell surface markers of IgG+veCD27−ve B cell population were analyzed by flow cytometry. Gating strategy is detailed in
Supplementary Figure 8. n = 13 HD donors and 16 RA donors. P-values calculated using Mann-Whitney test. Further surface markers are shown in
Supplementary Figure 8. (F) (i) Representative histogram plots of relevant fluorescence minus one (FMO) shown with open black line, healthy donor IgG+veCD27−ve
(shaded black line) and RA IgG+veCD27−ve (shaded red line). (ii) Mean Fluorescence Intensity (MFI) data for individual samples was plotted for HD (gray) and RA (red)
IgG+ve CD27−ve B cells. P-values were calculated using the Mann-Whitney test. n = 13 HD donors and 16 RA donors. (G) IgG+veCD27−ve B cells were also analyzed
for dual staining of CD24 and CD38 by flow cytometry. Percentage was plotted for HD (gray) and RA (red) for both IgG+veCD27−ve (filled symbol) and IgG+veCD27+ve
(open symbol) populations. For comparison of HD and RA IgG+ve CD27−ve populations P-values were obtained using Mann-Whitney test. For comparison of RA
IgG+veCD27−ve to RA IgG+ve CD27+ve populations, P-values were obtained using Wilcoxon paired test. (H) Percentage of CD20+veCD19+ve CD11c+ T-Bet+ve B cells
within RA PBMC IgG−veCD27−ve, IgG+veCD27+ve and IgG+veCD27−ve B cells. IgG+ve B cell populations had a higher percentage of CD11c+ T-Bet+ve B cells than
IgG−veCD27−ve, but there was no significant difference in the percentages of CD11c+ T-Bet+ve B cells within IgG+ve B cells. n = 8 RA donors. P-value calculated
using Wilcoxon matched-pair test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
compared to the healthy controls (p < 7.31× 10−7) (Figure 2C).
This demonstrates that RA patients generate considerably more
IgG+ve B cells that utilize a poorly mutated IGHV4-34 allele.
The IGHV4-34 allele is unusual in that it contains an Ala-Val-
Tyr (AVY) motif (within the framework 1 region) responsible for
the self-reactivity toward I/i carbohydrate antigens (31, 36, 37).
There was a slightly greater proportion of intact (unmutated)
AVY motifs in RA donors compared to healthy controls, in
sequences of either the IgG or IgM isotype; although this effect
was weak and only passed the threshold of significance for
sequences of the IgM isotype (Figure 2D). The Asn-X-Ser N-
glycosylation site (NHS) in the CDR2 region is associated with
binding to commensal bacteria by innate like B cells (38) and
is usually mutated in IgG+ve B cells (35). In RA patients the
proportion of IGHV4-34 IgG sequences where the NHS N-
glycosylation motif was still intact was significantly higher in
both IgG and IgM isotype sequences compared to healthy control
donors (Figure 2E).
IgGhypoM Sequences Are Polyclonal
To confirm the polyclonal nature of the IgGhypoM BCR
sequences, an equality metric called the Gini coefficient was
used to compare the degree of clonal expansion in the hypo-
and hyper-mutated compartments of each patient’s repertoire.
The Gini coefficients of the IgGhypoM and the IgG sequences
with 5 or more mutations (defined here as hypermutated) from
each patient within cohort 2 were similar, indicating that both
components of the repertoire have similar clonotypic frequency
structures (Figure 3A). We further investigated the degree of
clonal dominance of IgGhypoM from RA donors at the time of
diagnosis and healthy controls derived from cohort 1 where an
average of 200,000 BCRs were sequenced per donor. Concurring
with two recently published reports on NGS of RA BCRs, the
majority of RA patients and healthy controls expressed some
clonotype frequencies >0.5% of the total sequence reads (39, 40)
(Figure 3B). Within these repertoires, both hypermutated and
IgGhypoM sequences exhibited a similar distribution of clonotype
frequencies, including a very large number of clonotypes with
single reads (Figure 3C). To investigate the effect of clonal
populations on the increased frequency of hypomutated IgG
sequences in RA patients, we collapsed groups of reads sharing
identical CDR3 amino acid sequences and with shared predicted
V allele identity into clonal groups. With each clone only
contributing once to the analysis, we again observed similar
results indicating that the increased frequency of IgGhypoM
sequences could not be explained simply by the presence of
plasmablasts or plasma cells (Supplementary Figure 5). One
explanation for the higher frequency of IgGhypoM in RA
donors could be the failure of enzymes involved in somatic
hypermutation (SHM), such as activation-induced cytidine
deaminase (AID) or the subsequent mismatch repair enzymes.
However, mutations were preferentially targeted to the same
regions of the IgGHV segment in RA and control donors, and
there were no inter-group differences in the targeting of mutation
(10) prevalence of IgGhypoM in RA donors did not result from
AID or mismatch repair enzyme impairment or to the mono-
or oligo-clonal expansions of IgG+ve BCRs with few mutations
Supplementary Figures 6, 7.
The BCRhypoM Are Expressed by
IgG+veCD27–ve B Cells
The proportion of IgGhypoM was significantly higher in the
IgG+veCD27−ve B-cell population from RA patients than from
either the IgG+veCD27+ve RA population or from the same
population in the healthy controls (Figure 4A, Mann-Whitney
U, p < 0.015). The absolute number of circulating peripheral
blood double negative (IgM−veIgD−veCD27−ve) B cells in RA
patients was also significantly increased at the time of diagnosis
and did not change following 6 months of synthetic DMARD
therapy (Figure 4B). Within individual RA patients, the number
of double negative B cells at baseline and following 6 months
of therapy was still clearly correlated, suggesting that they did
not decrease significantly with DMARD treatment (Figure 4C;
Supplementary Table 3C for patient data). Importantly the
increase in double negative B cells was also reflected in a
significant increase in the frequency of IgG+veCD27−ve B
cells (Figure 4D). Circulating IgG+veCD27−ve B-cells from RA
patients expressed less CD24, CD21, and CD38, but similar
levels of CD73 and CD1c when compared to the same subset
in healthy controls (Figures 4E,F; Supplementary Figure 8). B
cells that lack expression of IgD, CD27, CD21, CD24, and CD38
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FIGURE 5 | (A) Flow cytometry plots of peripheral blood IgG+veCD27−ve B cells stained for CD21, CD24, and CD38, taken from RA patients at the time of
undergoing arthroplasty and compared to healthy donor PBMC. (B) (i) Flow cytometry of paired peripheral blood (PBMC) and synovial tissue (SynT) B cells from RA
patients taken at the time of undergoing arthroplasty. The graph shows the percentage of IgG+ve B cells within the CD20+veCD19+ve B cell population. (ii) Percentage
of CD20+veCD19+ve IgG+veCD27−ve B cells within the IgG+veCD20+veCD19+ve B cell population. For (i) and (ii) n = 24 RA donors. P-value calculated using paired
t-test. (iii) Paired RA PBMC and synovial tissue B cells within the IgG+veCD27−ve B cells stained for CD21, CD24 and CD38. n = 6 donors. P-value calculated using
Wilcoxon matched-pair T-test. (C) Representative histogram plots of isotype control shown with open black line, PBMC IgG+veCD27−ve (shaded black line) and
(Continued)
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FIGURE 5 | synovial Tissue IgG+veCD27−ve (shaded red line) (i). (ii) Mean Fluorescence Intensity (MFI) data for individual samples was plotted (ii) for PBMC (gray) and
SynT (red) for IgG+ve CD27−ve B cells. n = 6 donors. P-values were calculated using the Wilcoxon paired test. Further surface marker data is shown in
Supplementary Figure 9. (D) PBMC and synovial tissue cells were stimulated for 4.5 h with PMA, Ionomycin and Brefeldin A, then stained for intracellular cytokines.
Representative flow cytometry plots showing the intracellular cytokine staining of synovial tissue IgG+veCD27−ve and IgG+veCD27+ve B cell subsets for TNF-alpha and
GM-CSF (i). Pooled data for PBMC and Synovial tissue (ii) TNF-alpha and (iii) GM-CSF. Each point represents an individual patient sample. n = 9 donors. P-values
calculated using Wilcoxon matched-pair test between tissue type or cell type. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
are known as double negative 2 (DN2) B cells, whilst DN1 B
cells express CD24 and CD38 (9). We observed a significant
increase in the percentage of IgG+veCD27−ve B cells that were
also negative for CD38 and CD24 staining, demonstrating that
DN2 cells were increased in RA peripheral blood (Figure 4G).
DN2 cells also express CD11c and T-bet and just over 10% of
the IgG+veCD27−ve (and IgG+veCD27+ve) B cells expressed both
these markers (Figure 4H).
IgG+veCD27–ve B Cells Are Enriched in the
Synovium and Secrete TNF-alpha
Utilizing blood samples from patients with established
seropositive RA (ESRA) undergoing joint arthroplasty and
comparing them to healthy donors (HD) further confirmed that
IgG+veCD27−ve B cells expressed significantly less CD21, CD24,
and CD38 (Figure 5A; cohort 4 in Supplementary Table 4).
Compared to paired peripheral blood (PBMC) samples, the RA
synovium was enriched for both IgG+ve B cells (Figure 5Bi) and
IgG+veCD27−ve B cells (Figure 5Bii). Specifically comparing
paired PBMC and synovial IgG+veCD27−ve B cells showed a
further reduction in the percentage of synovial IgG+veCD27−ve
B cells that expressed CD21, CD38, and CD5 but a rise in CD24
expression (Figures 5Biii,C; Supplementary Figures 9B–D).
When PBMC and synovial B cells were stimulated [with
PMA/Ionomycin], synovial IgG+veCD27−ve B-cells expressed
significantly more TNF-alpha than either the peripheral blood
naïve (IgG−veCD27−ve), memory (IgG+veCD27−ve) or double
negative B-cell populations and synovial naïve and memory
B-cells. In contrast the production of GM-CSF was similar
(Figure 5D). This data shows that IgG+veCD27−ve B-cells
express significantly more IgGhypoM and within the synovium
they are primed to secrete more TNF than either memory or
naive B cells.
Peripheral Blood and Synovial B Cell
Repertoires Are Distinct in RA
As well as secreting cytokines, synovial B cells are reported
to secrete autoantibodies that have undergone SHM within
GC like structures (39, 41–43). Paired peripheral and synovial
IgGHV sequences from RA patients undergoing arthroplasty
were sequenced (Figure 6A). To avoid any potential confounding
that may occur with increased levels of mRNA in plasma cells,
only purified CD20+ve B cells were analyzed. In six out of
eight patients, the lower quartile of the distribution of somatic
mutations was lower in the periphery than in the synovium.
The mean number of mutations displayed by the peripheral
B cell repertoire of patients (mean 15.27 ± 5.09) was lower
than the mean number of mutations displayed by the paired
synovial repertoires (mean 19.65 ± 2.96, paired t-test, p = 0.02).
To exclude the effects of read duplication and to account for
the presence of similar clones, the distribution of the number
of IgGHV mutations was also plotted following single-linkage
clonal clustering (Supplementary Figure 10). This removed the
peaks associated high abundance sequence reads but in 7 of 8
patients, the distributions of the mean number of mutations
per clonal cluster had a lower, more skewed distribution in
peripheral blood than in the synovium. The RA synovium has
been reported to harbor clonal expansions of B cells (39, 43).
The percentage of the repertoire composed of each unique CDR3
clonotype was plotted, dividing the BCR sequences into those
with greater or fewer than five mutations relative to the predicted
germ line sequence (Figure 6B). No clear preference was noted
within either the hypermutated or IgGhypoM sequences in terms
of CDR3 clonal frequencies with all four populations expressing
CDR3 clonal frequencies>0.5% of the IgG+ve B cell repertoire. A
caveat to these observations was that, due to the smaller number
of B cells purified from the synovium of ESRA patients, we
utilized the Smart-seq2 protocol to amplify BCR RNA from both
the blood and synovial samples (15). This afforded a greater
opportunity for amplification bias, which may have increased the
relative frequencies of abundant clones.
Finally, it was important to determine if RA patients
shared BCR sequences that may point to particular pathogenic
clonal expansions. The term “public sequence” is used to
describe similar or identical T cell receptor (TCR) or BCR
sequences which may arise in different individuals, indicative
of a convergent immune response in different individuals to
a common antigenic stimulus (44). This may have particular
relevance for autoimmunemediated tissue damage including RA.
We hypothesized that identical CDR3 sequences would be found
in more than one patient in newly diagnosed DMARD naïve
RA patients (cohort 1). Instead, we found that the degree of
sharing of clonal sequence clusters between the peripheral blood
repertoires of RA donors was no greater than between healthy
donors (Supplementary Figure 11).
Finally, to ask if the IgGhypoM sequences arose in the
synovium, the frequency of identical CDR3 sequence clones
present in the blood and synovium of the same RA patient
was assessed. Very few CDR3 sequences were present in both
the blood and synovium of the same patient (Figure 6C).
Where overlap was seen (in the repertoires of 5 RA patients),
it made up <0.1% of the synovial repertoire. Clonal lineage
analysis of all shared sequences was employed to detect egression
events from the synovial compartment. Only two lineage trees,
from patient B and patient K, showed evidence of egression
events from the synovium to the periphery (Figure 6D),
Frontiers in Immunology | www.frontiersin.org 10 March 2020 | Volume 11 | Article 395
Cowan et al. RA BCRs Show Fewer Hypermutations
FIGURE 6 | (A) Distributions of mutation counts from paired peripheral blood (blue) and synovial (red) IgG sequence repertoires from each of 8 RA patients with ESRA
undergoing arthroplasty. The central horizontal line indicates the median of each distribution, with the upper and lower dashed lines representing the upper and lower
quartiles, respectively. (B) Percentage of the repertoire composed of each CDR3 clonotype for paired synovial (S) and peripheral blood (P) samples from each of the 8
RA patients shown in (A) (cohort 4). (C) Repertoire overlap of synovial (red) and peripheral blood (blue) IgG repertoires of the RA patients. Each Venn diagram
represents a single patient. The number of unique, non-singleton IgG sequences in the repertoire from each compartment is depicted at the center of each circle, and
shared sequences are enumerated at the intersection between the two circles. Two shared sequences are considered identical if they possessed the same CDR3
nucleotide sequence and used the same V and J gene segments. (D) Lineage trees of B cell clones that show evidence of egression from the synovium into the
periphery of RA patients, inferred for (i) clone 36 from patient B and (ii) clone 282 from patient K. Each node represents a unique non-singleton IgG sequence with the
size of the node scales non-linearly in proportion to the number of sequence duplicated observed. The label at the center of each node represents the tissue origin of
the sequence, and node color indicates the number of somatic mutations present in the clone sequence. Red arrows mark egression events from the synovium to the
periphery. Lineage trees were inferred using PHYLIP v3.6 and plotted in Gephi v0.92.
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with the other sharing events feasibly explained by index
misassignment in sequencing. Given the extremely low support
for egression events from the synovium, there is no evidence
to support the hypothesis that the IgGhypoM sequences in the
peripheral blood B cell repertoires arise within the inflamed
synovial joint.
DISCUSSION
This is the largest study to date, utilizing NGS, to examine the
IgGHV repertoires of over 150 RA and 15 Sjögren’s syndrome
patients. RA patients express significantly more hypomutated
BCRs within IgG+veCD27−ve B cells. In patients with established
RA, IgG+veCD27−veB cells are enriched in the synovium, where
they secrete TNF upon activation. The presence of IgGhypoM
sequences was also seen in patients with Sjögren’s syndrome,
indicating that this maybe a general feature of dysregulated B cell
homeostasis in human autoimmunity. Significantly more IgGHV
express a poorly mutated IGHV4-34 allele, which is known to
be self-reactive in the germ line configuration. We hypothesize
that auto-antibodies capable of driving chronic inflammation
may arise from both peripheral and synovial B cells expressing
IgGhypoM, via the formation of immune complexes and pro-
inflammatory cytokines. We further hypothesize that following B
cell depletion therapy, the frequency of IgGhypoM would gradually
increase to a critical threshold prior to a flare of synovitis. Future
studies will confirm if the IgGhypoM bind auto-antigens and their
pattern of re-emergence following BCDT.
The stimuli driving the development of a high frequency of
class switched IgGhypoM in both RA and Sjögren’s syndrome
patients, is currently unknown. Central and peripheral tolerance
checkpoints are known to be defective in RA patients, leading to
the accumulation of naïve autoreactive B cells in the periphery
(45). Activation of naïve B cells, facilitated by T cell help and/or
TLR ligands, induces class switching out-with the germinal
center (46). An extrafollicular response has been shown to drive
the expansion of autoreactive barely mutated B cells in mice,
that have the potential to cause arthritis or systemic lupus
erythematosus (SLE) (47). In addition, humans with SLE have
significant expansions of poorly mutated IgG VH4-34 at the time
of disease flares (11). The high frequency of IgGhypoM in RA
patients suggests that they may have arisen from an ongoing
extrafollicular response.
DN2 B cells may function as extrafollicular antibody secreting
precursor cells, that arise from activated naïve B cells and
have fewer somatic mutations within the BCR variable region
than IgG+veCD27+ve memory B cells (9). DN2 cells also
express CD11c and the transcription factor T-bet and are
greatly expanded in patients with active SLE (10). In RA
patients we observed a significant increase in peripheral blood
IgG+veCD27−veCD24−veCD38−ve B cells. CD21 expression on
IgG+veCD27−ve B cells was reduced compared to healthy
controls. Whilst this indicates that DN2 cells are increased in RA
patients we cannot say if IgGhypoM are also definitively derived
from DN2 B cells and future studies will address this.
A previous report alludes to the loss of clonally expanded
populations of B cells from the peripheral blood into the
synovium at the time of RA onset (40). Assessing a greater
number of IgG sequences at diagnosis, we observed expanded
populations of B cells in both RA and healthy controls, making
it difficult to see how dominant BCR clones could predict the
onset of RA in at-risk individuals. In addition, there was no
greater degree of sharing of clonal sequence clusters between RA
patients, when compared to healthy controls, which does not
support the paradigm that RA is driven by a specific repertoire
of pathogenic B cell clones. Repertoire overlap analysis also
demonstrated a very low number of multi-compartmental IgG
sequences when compared to the overall size of either repertoire,
suggesting that the peripheral and synovial B cell repertoires are
quite distinct within and between patients, with only low levels of
sharing of identical clones between the compartments. The cause
for this may, as previously reported, arise from the migration
of peripheral blood B cells into the synovium (40). As synovial
B cells express distinct chemokine receptors from peripheral B
cells, they may be sequestered within the synovium and rarely
be observed in the peripheral blood again (48). In line with this,
we observed only two B cell clones that showed evidence of a
migration event from the synovium into the peripheral blood,
indicating that such events are rare and not the source of the
peripheral blood IgGhypoM B cells.
Over time an increasing number of RA patients are failing to
respond to multiple synthetic and biologic DMARD therapies.
Future studies will explore if these refractory RA patients express
more IgGhypoM double negative B cells and if their emergence
following BCDT foretells clinical disease relapse.
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